Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Urticaria

Urticaria

Part of Hypersensitivity, Immediate

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Urticaria

12 trials tracked for Urticaria: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 21 citations.

12Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 3 1 Phase 2 4 Phase 1 1 Other / NA 4
  1. Phase 4 A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria Completed · 21 cited
  2. Phase 4 Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria Completed
  3. Phase 3 An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201) Completed
  4. Phase 2 Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy Completed
  5. Phase 2 Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Completed
  6. Phase 2 Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares Completed
Show 6 more trials
  1. Phase 2 A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU). Completed
  2. Phase 1 Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264 Completed
  3. N/A The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment Completed
  4. N/A Safety of Aerius Syrup in Pediatric Patients Aged 1-5 Years Old With Allergic Rhinitis or Chronic Idiopathic Urticaria (Study P04446AM1)(COMPLETED) Completed
  5. N/A Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria Completed
  6. N/A Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634) Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Urticaria: what the trials found

Omalizumab significantly reduces the risk of clinical worsening in chronic idiopathic urticaria (CIU), as measured by UAS7 ≥12 (21.0% vs 60.4%, p<0.0001) and UAS7 >6 (32.1% vs 64.2%, p=0.0004), and prolongs time to worsening (median 12.0 weeks vs not reached, p<0.0001) 3. Desloratadine improves pruritus/itch and rash scores from Day 3 through Week 2 compared to placebo (e.g., sum score change at Week 2: -3.19 vs -2.02, p<0.001) 5. Additional trials support the efficacy of desloratadine in urticaria 1112.

Bilastine has been studied in urticaria 4. Povorcitinib, a recent phase 2 trial, did not show statistically significant differences versus placebo for UAS7 change at Week 12 (p=0.8298), UAS7 ≤6 (p=0.9366), or UAS7=0 (p=0.9469) 2. ARS-1 was evaluated in a small phase 2 trial 1.

Recent results — preliminary, needs further review

  • Povorcitinib (phase 2, N=136) did not demonstrate significant improvement in UAS7 or disease control endpoints at Week 12 compared to placebo 2.
  • ARS-1 (phase 2, N=21) was evaluated for pruritus/hive scores, but results are preliminary and not yet corroborated 1.

For the clinician treating this condition

  • Omalizumab is effective for preventing clinical worsening in CIU, with significant reductions in UAS7 worsening and prolonged time to worsening.
  • Desloratadine provides rapid and sustained improvement in pruritus and rash symptoms in urticaria.
  • Recent phase 2 data on povorcitinib and ARS-1 do not yet support their use in urticaria.

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Vitamin D supplementation alleviates symptoms of allergic rhinitis, atopic dermatitis, and urticaria
Allergy & Immunology Meta-analysis
Vitamin D supplementation alleviates symptoms of allergic rhinitis, atopic dermatitis, and urticaria Vitamin D shows specific benefits for some allergic skin and respiratory conditions
This umbrella review synthesized data from 66,387 patients regarding vitamin D's role in allergic diseases. The analysis found that vitamin …
New data suggests vitamin D may help manage symptoms of itchy skin and runny noses, though its effects vary by condition.
Frontiers Jun 29, 2026
First Report of Vedolizumab-Associated Recall Urticaria in a Case Report and Literature Review
Allergy & Immunology Sys. Review
First Report of Vedolizumab-Associated Recall Urticaria in a Case Report and Literature Review Why Hives Return to Old Injection Spots
This case report and literature review describes the first documented instance of vedolizumab-associated recall urticaria in a 25-year-old m…
A new case report reveals a rare skin reaction where hives return strictly to past injection sites.
Frontiers Apr 21, 2026
Neuroimmune mechanisms may sustain urticaria pruritus and contribute to treatment resistance
Allergy & Immunology Sys. Review
Neuroimmune mechanisms may sustain urticaria pruritus and contribute to treatment resistance Why do some hives keep itching? New research points to a brain-immune connection
A systematic review synthesizes evidence on neuro-immune interactions in urticaria, suggesting these mechanisms amplify pruritic signaling a…
Chronic hives may persist due to a brain-immune feedback loop that amplifies itching and inflammation, making some treatments less effective…
Frontiers Apr 2, 2026